X0306 4 2022-01-01 0 0001340652 ChemoCentryx, Inc. CCXI 0001423084 Schall Thomas J. C/O CHEMOCENTRYX, INC. 835 INDUSTRIAL ROAD, SUITE 600 SAN CARLOS CA 94070 1 1 0 0 President and CEO Common Stock 2022-01-01 4 M 0 23334 0.00 A 2378150 D Common Stock 2022-01-01 4 M 0 34567 0.00 A 2412717 D Common Stock 2022-01-01 4 M 0 26333 0.00 A 2439050 D Common Stock 2022-01-01 4 F 0 45698 36.41 D 2393352 D Restricted Stock Units 2022-01-01 4 M 0 23334 D Common Stock 23334 0 D Restricted Stock Units 2022-01-01 4 M 0 34567 D Common Stock 34567 34567 D Restricted Stock Units 2022-01-01 4 M 0 26333 D Common Stock 26333 52667 D Shares were acquired upon vesting of restricted stock units awarded on March 4, 2019. Shares were acquired upon vesting of restricted stock units awarded on March 3, 2020. Shares were acquired upon vesting of restricted stock units awarded on February 25, 2021. Represents shares withheld upon vesting of restricted stock units to satisfy tax withholding obligation. Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. The restricted stock units awarded on March 4, 2019, vest in three equal installments on January 1, 2020, January 1, 2021, and January 1, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. The restricted stock units awarded on March 3, 2020, vest in three equal installments on January 1, 2021, January 1, 2022, and January 1, 2023, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. The restricted stock units awarded on February 25, 2021, vests in three equal installments on January 1, 2022, January 1, 2023, and January 1, 2024, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. /s/ Susan M. Kanaya, as Attorney-in-Fact 2022-01-04